Overview

High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-07-02
Target enrollment:
Participant gender:
Summary
To compare the efficacy of high dose rosuvastatin preloading vs placebo before primary PCI in terms of MACE at 30 days
Phase:
PHASE2
Details
Lead Sponsor:
Sheikh Zayed Federal Postgraduate Medical Institute
Collaborator:
Punjab Institute of Cardology
Treatments:
Atorvastatin
Rosuvastatin Calcium